Daniel Erny

Daniel Erny

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
DEDaniel Erny
Daniel Erny
AAAnna Lena Hrabě de Angelis
Anna Lena Hrabě de Angelis
DJDiego Jaitin
Diego Jaitin
PWPeter Wieghofer
Peter Wieghofer
OSOri Staszewski
Ori Staszewski
MPMarco Prinz
Marco Prinz

20 January 2013 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
KKKatrin Kierdorf
Katrin Kierdorf
DEDaniel Erny
Daniel Erny
TGTobias Goldmann
Tobias Goldmann
VSVictor Sander
Victor Sander
CSChristian Schulz
Christian Schulz
MPMarco Prinz
Marco Prinz

1 December 2019 in Cell
Verified
Journal Article
Closed access
LGLaufey Geirsdottir
Laufey Geirsdottir
EDEyal David
Eyal David
HKHadas Keren-Shaul
Hadas Keren-Shaul
AWAssaf Weiner
Assaf Weiner
SBStefan Cornelius Bohlen
Stefan Cornelius Bohlen
MPMarco Prinz
Marco Prinz

22 March 2017 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MPMarco Prinz
Marco Prinz
DEDaniel Erny
Daniel Erny
NHNora Hagemeyer
Nora Hagemeyer

3 August 2011 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
AMAlexander Mildner
Alexander Mildner
BSBernhard Schlevogt
Bernhard Schlevogt
KKKatrin Kierdorf
Katrin Kierdorf
CBChotima Böttcher
Chotima Böttcher
DEDaniel Erny
Daniel Erny
MPMarco Prinz
Marco Prinz
Mononuclear phagocytes are important modulators of Alzheimer's disease (AD), but the specific functions of resident microglia, bone marrow-derived mononuclear cells, and perivascular macrophages have not been resolved. To elucidate the spatiotemporal roles of mononuclear phagocytes during disease, we targeted myeloid cell subsets from different compartments and examined disease pathogenesis in three different mouse models of AD (APPswe/PS1,APPswe, andAPP23mice). We identified chemokine receptor 2 (CCR2)-expressing myeloid cells as the population that was preferentially recruited to β-amyloid (Aβ) deposits. Unexpectedly, AD brains with dysfunctional microglia and devoid of parenchymal bone marrow-derived phagocytes did not show overt changes in plaque pathology and Aβ load. In contrast, restriction of CCR2 deficiency to perivascular myeloid cells drastically impaired β-amyloid clearance and amplified vascular Aβ deposition, while parenchymal plaque deposition remained unaffected. Together, our data advocate selective functions of CCR2-expressing myeloid subsets, which could be targeted specifically to modify disease burden in AD.

3 March 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
OMOmar Mossad
Omar Mossad
BBBérénice Batut
Bérénice Batut
BYBahtiyar Yilmaz
Bahtiyar Yilmaz
NDNikolaos Dokalis
Nikolaos Dokalis
CMCharlotte Mezö
Charlotte Mezö
TBThomas Blank
Thomas Blank